AI-Derived Splenic Response in Cardiac PET Predicts Mortality: A Multi-Site Study

AI 衍生的脾脏反应在心脏 PET 中预测死亡率:一项多中心研究

阅读:1

Abstract

BACKGROUND: Inadequate pharmacologic stress may limit the diagnostic and prognostic accuracy of myocardial perfusion imaging (MPI). The splenic ratio (SR), a measure of stress adequacy, has emerged as a potential imaging biomarker. OBJECTIVES: To evaluate the prognostic value of artificial intelligence (AI)-derived SR in a large multicenter (82)Rb-PET cohort undergoing regadenoson stress testing. METHODS: We retrospectively analyzed 10,913 patients from three sites in the REFINE PET registry with clinically indicated MPI and linked clinical outcomes. SR was calculated using fully automated algorithms as the ratio of splenic uptake at stress versus rest. Patients were stratified by SR into high (≥90th percentile) and low (<90th percentile) groups. The primary outcome was major adverse cardiovascular events (MACE). Survival analysis was conducted using Kaplan-Meier and Cox proportional hazards models adjusted for clinical and imaging covariates, including myocardial flow reserve (MFR ≥2 vs. <2). RESULTS: The cohort had a median age of 68 years, with 57% male patients. Common risk factors included hypertension (84%), dyslipidemia (76%), diabetes (33%), and prior coronary artery disease (31%). Median follow-up was 4.6 years. Patients with high SR (n=1,091) had an increased risk of MACE (HR 1.18, 95% CI 1.06-1.31, p=0.002). Among patients with preserved MFR (≥2; n=7,310), high SR remained independently associated with MACE (HR 1.44, 95% CI 1.24-1.67, p<0.0001). CONCLUSIONS: Elevated AI-derived SR was independently associated with adverse cardiovascular outcomes, including among patients with preserved MFR. These findings support SR as a novel, automated imaging biomarker for risk stratification in (82)Rb PET MPI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。